Telix Pharmaceuticals (TLX) Enterprise Value (2023 - 2025)
Telix Pharmaceuticals (TLX) posted quarterly Enterprise Value of -$141.9 million for Q4 2025, up 69.46% year-over-year from -$83.7 million in Q4 2024, and up 69.46% quarter-over-quarter from -$464.5 million in Q4 2024.
Telix Pharmaceuticals (TLX) Enterprise Value (2023 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Enterprise Value for 3 consecutive years, with -$141.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Enterprise Value rose 69.46% year-over-year to -$141.9 million; the TTM figure through Dec 2025 stood at -$141.9 million (up 69.46% YoY), while the FY2025 annual figure was -$141.9 million, up 69.46% from the prior year.
- Enterprise Value advanced to -$141.9 million in Q4 2025 per TLX's latest filing, from -$464.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$80.2 million in Q4 2023 and bottomed at -$464.5 million in Q4 2024.
- Historically, Enterprise Value has averaged -$228.9 million across 3 years, with a median of -$141.9 million in 2025.
- Annual changes were most pronounced in 2024 — Enterprise Value plunged 479.03% — and 2025, when it soared 69.46%.
- Telix Pharmaceuticals' Enterprise Value stood at -$80.2 million in 2023, then slumped by 479.03% to -$464.5 million in 2024, then jumped by 69.46% to -$141.9 million in 2025.
- Business Quant data shows TLX's Enterprise Value at -$141.9 million in Q4 2025, -$464.5 million in Q4 2024, and -$80.2 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Telix Pharmaceuticals | 4.00 Bn | 3.86 Bn | - | -141.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -141.87 Mn |
| Dec 31, 2024 | -464.54 Mn |
| Dec 31, 2023 | -80.23 Mn |